ICAHN School of Medicine At Mount Sinai

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1963-01-01

Employees: 5K

Market Cap: -

Website: http://www.mssm.edu

Clinical Trials

Mobile Ostomates Resources for Patients and Caregivers

Not Applicable

Active, not recruiting

Conditions: Bladder Cancer
Colorectal Cancer

Interventions: Other: Usual Care
Other: STOMA Care web-based application

First Posted Date: 2023-12-06

Last Posted Date: 2024-07-03

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 90

Registration Number: NCT06157814

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Psychopharmacological Treatment of Emotional Distress

Phase 4

Recruiting

Conditions: Psychological Distress
Suicide Crisis Syndrome

Interventions: Drug: Clonazepam
Drug: Olanzapine
Drug: Buprenorphine

First Posted Date: 2023-11-15

Last Posted Date: 2024-06-07

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 80

Registration Number: NCT06133114

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Investigation of a 3 oz Water Protocol on Patients With Tracheostomies

Recruiting

Conditions: Tracheostomy

Interventions: Other: 3 Oz water screen

First Posted Date: 2023-11-07

Last Posted Date: 2024-05-09

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 80

Registration Number: NCT06120790

Locations: 🇺🇸
Mount Sinai Hospital, New York, New York, United States

Family-Based Interoceptive Exposure for Avoidant Restrictive Food Intake Disorder

Not Applicable

Suspended

Conditions: Avoidant Restrictive Food Intake Disorder

Interventions: Behavioral: MBIE

First Posted Date: 2023-11-01

Last Posted Date: 2024-10-01

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 57

Registration Number: NCT06110806

Locations: 🇺🇸
Department of Psychiatry, Eating and Weight Disorders Program, New York, New York, United States

Spesolimab in Pyoderma Gangrenosum

Phase 2

Recruiting

Conditions: Pyoderma Gangrenosum

Interventions: Drug: Spesolimab

First Posted Date: 2023-10-23

Last Posted Date: 2024-05-02

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 20

Registration Number: NCT06092216

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Biological: Dupilumab
Biological: Cemiplimab

First Posted Date: 2023-10-18

Last Posted Date: 2024-03-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 21

Registration Number: NCT06088771

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

The Computational and Neural Mechanisms Linking Decision-making and Memory in Humans

Not Applicable

Recruiting

Conditions: Memory, Short-Term

First Posted Date: 2023-10-10

Last Posted Date: 2023-11-15

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 25

Registration Number: NCT06072378

Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment

Phase 2

Recruiting

Conditions: Depression
Mild Cognitive Impairment

Interventions: Drug: IV Ketamine

First Posted Date: 2023-10-06

Last Posted Date: 2023-10-25

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 15

Registration Number: NCT06069843

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai (Depression and Anxiety Center), New York, New York, United States

Maternal And Infant Antipsychotic Study

Recruiting

Conditions: Pregnancy
Antipsychotics

Interventions: Drug: Non-antipsychotic medication
Other: No Medication
Drug: Antipsychotics

First Posted Date: 2023-09-22

Last Posted Date: 2024-08-05

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 200

Registration Number: NCT06049953

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Phase 1

Recruiting

Conditions: Ovarian Cancer
Malignant Neoplasm of Uterus

Interventions: Drug: Sacituzumab
Drug: Cisplatin

First Posted Date: 2023-09-18

Last Posted Date: 2024-10-31

Lead Sponsor: Icahn School of Medicine at Mount Sinai

Target Recruit Count: 54

Registration Number: NCT06040970

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy